Daily non-political popular news in brief.
Doctors conclude temsirolimus is effective new treatment for advanced renal cell carcinoma
05-30-2007 · EurekAlert!The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show temsirolimus improved overall survival when compared to the current treatment for this stage of disease.
Read more »
Keywords: doctors, conclude, temsirolimus, effective, treatment, advanced, renal, cell, carcinoma, doctor, temsirolimu
« Previous | Next »
Similar news on "Doctors conclude temsirolimus is effective new treatment for advanced renal cell carcinoma":
- Researchers find stem-cell therapy effective in targeting metastatic cancer
12-20-2006 · EurekAlert!
Patients with advanced cancer that has spread to many different sites often do not have many treatment options, since they would be unable to tolerate the doses of treatment they would need to kill the tumors.
Similar news · Read more »
- GSK's Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
06-02-2007 · EurekAlert!
GlaxoSmithKline (GSK) today announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer. These trials were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results observed in these trials with pazopanib support further investigations.
Similar news · Read more »
- GSK's Pazopanib shows positive results in patients with advanced renal cell carcinoma
06-02-2007 · EurekAlert!
GlaxoSmithKline (GSK) today announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) . These trials were presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results observed in these trials with pazopanib support further investigations.
Similar news · Read more »
- Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
01-10-2007 · EurekAlert!
Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the New England Journal of Medicine has published their pivotal Phase III trial demonstrating that Nexavar (sorafenib) tablets doubled median progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), or kidney cancer.
Similar news · Read more »
- Proton beam therapy may improve treatment of rare but aggressive tumor
11-20-2006 · EurekAlert!
Proton beam radiation therapy, a very precise type of radiation treatment, may be an effective treatment for advanced adenoid cystic carcinoma that has spread to the cranial base.
Similar news · Read more »
- EMEA and FDA extend drug-label based on results of the EORTC 24971 trial
10-20-2006 · EurekAlert!
In its September meeting 2006, the European Medicines Agency (EMEA) gave a positive opinion to include the use of docetaxel in combination with the current standard treatment -- cisplatin and 5-fluorouracil -- for the induction treatment of patients with inoperable locally advanced squamous cell carcinoma of the head and neck. On October 18, the U.S. Food and Drug Administration (FDA) gave its approval to the new treatment as well.
Similar news · Read more »
- Cisplatin is more effective than carboplatin for treating nonsmall cell lung cancer
06-05-2007 · EurekAlert!
Some patients with advanced nonsmall cell lung cancer have slightly higher survival rates when treated with the chemotherapy drug cisplatin than another platinum-based drug, carboplatin, according to a study in the June 6 Journal of the National Cancer Institute. The authors conclude that cisplatin chemotherapy should remain the standard of care for these patients.
Similar news · Read more »
- Sutent achieves first line EAU approval for kidney cancer
03-22-2007 · EurekAlert!
Sutent (sunitinib malate) has received a European Association of Urology recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma.
Similar news · Read more »
- In 'spontaneous' liver cancer, Lombardi researcher sees a cure
06-19-2007 · EurekAlert!
Adding more good news to last week's announcement that Nexavar (sorafenib) may be the first effective treatment for advanced liver cancer, researchers at the Lombardi Comprehensive Cancer Center at Georgetown University have uncovered a new molecular mechanism that may "spontaneously" cause liver cancer.
Similar news · Read more »
- Eltrombopag effective for hepatitis C patients with low blood-platelet counts
12-28-2007 · EurekAlert!
For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease. This problem is compounded by the fact that standard antiviral treatment for the disease can further reduce platelet numbers to dangerously low levels, effectively denying these patients the treatment they urgently need. Now, research published in the New England Journal of Medicine finds that a new drug, eltrombopag, appears to significantly boost platelet counts, opening the door to effective treatment.
Similar news · Read more »
